<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884685</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-nCOV-2001</org_study_id>
    <nct_id>NCT04884685</nct_id>
  </id_info>
  <brief_title>Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅱb Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Research and Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blinded, placebo-controlled, phase Ⅱb clinical trial of an&#xD;
      inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development&#xD;
      Co., Ltd..The purpose of this study is to evaluate the safety of the SARS-CoV-2 Inactivated&#xD;
      vaccine in healthy children and adolescents aged 3-17 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blinded, placebo-controlled,phase Ⅱb clinical trial in&#xD;
      children and adolescents aged 3-17 years. The experimental vaccine and placebo were both&#xD;
      manufactured by Sinovac Research and Development Co., Ltd.. A total of 500 subjects will be&#xD;
      enrolled, including 100 children aged 3-5 years, 200 children aged 6-11 years and 200&#xD;
      adolescents aged 12-17 years. Each age group will be randomly divided into two groups in a&#xD;
      3:1 ratio and received two doses of experimental vaccine or placebo on on day 0 and day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">January 3, 2022</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety index-incidence of adverse reactions</measure>
    <time_frame>Day 0-28 after each dose</time_frame>
    <description>Incidence rate of adverse reactions occured from the beginning of the vaccination to 28 days after the second dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety index-incidence of adverse reactions</measure>
    <time_frame>Day 0-7 after each dose vaccination</time_frame>
    <description>Incidence rate of adverse reactions within 7 days after each dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-incidence of serious adverse events</measure>
    <time_frame>From the beginning of the vaccination to 6 months after the second dose vaccination</time_frame>
    <description>Incidence rate of serious adverse events from the beginning of the vaccination to 6 months after the second dose vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine . Vaccine will given by intramuscular injection on day 0 and day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will receive two doses of placebo. The placebo will given by intramuscular injection on day 0 and day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 Inactivated Vaccine</intervention_name>
    <description>600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>aluminium hydroxide solution only</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy children and adolescents aged 3-17 years;&#xD;
&#xD;
          -  The subjects and/or guardians can understand and voluntarily sign the informed consent&#xD;
             form (For subjects aged 8-17 years, both subjects and guardians need to sign the&#xD;
             informed consent form);&#xD;
&#xD;
          -  Proven legal identity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Travel history / residence history of communities with case reports within 14 days;&#xD;
&#xD;
          -  History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within&#xD;
             14 days;&#xD;
&#xD;
          -  Have contacted patients with fever or respiratory symptoms from communities with case&#xD;
             reports within 14 days;&#xD;
&#xD;
          -  Two or more cases of fever and / or respiratory symptoms in a small contact area of&#xD;
             volunteers, such as home, office etc. within 14 days;&#xD;
&#xD;
          -  History of SARS-CoV-2 infection;&#xD;
&#xD;
          -  History of asthma, history of allergy to the vaccine or vaccine components, or serious&#xD;
             adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;&#xD;
&#xD;
          -  Congenital malformations or developmental disorders, genetic defects, severe&#xD;
             malnutrition, etc.;&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency / immunosuppression;&#xD;
&#xD;
          -  Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes&#xD;
             that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;&#xD;
&#xD;
          -  Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;&#xD;
&#xD;
          -  Thyroid disease or history of thyroidectomy, spleenlessness, functional&#xD;
             spleenlessness, spleenlessness or splenectomy resulting from any condition;&#xD;
&#xD;
          -  Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors,&#xD;
             blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;&#xD;
&#xD;
          -  Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding&#xD;
             allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis&#xD;
             superficial corticosteroid therapy) in the past 6 months;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Acute diseases or acute exacerbation of chronic diseases in the past 7 days;&#xD;
&#xD;
          -  Receipt of blood products within in the past 3 months;&#xD;
&#xD;
          -  Receipt of other investigational drugs in the past 30 days;&#xD;
&#xD;
          -  Receipt of attenuated live vaccines in the past 14 days;&#xD;
&#xD;
          -  Receipt of inactivated or subunit vaccines in the past 7 days;&#xD;
&#xD;
          -  Axillary temperature &gt;37.0°C;&#xD;
&#xD;
          -  Already pregnant (including a positive urine pregnancy test) or are breastfeeding,&#xD;
             planning to get pregnant within 3 months;&#xD;
&#xD;
          -  According to the investigator's judgment, the subject has any other factors that are&#xD;
             not suitable for participating in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuliang Zhao, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hubei Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zanhuang county Center for Disease Control and Prevention</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>051230</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

